Indeed, the percentage of HER2+ patients was 4-time higher in the MARCKS-positive vs. MARCKS-negative nIBC patients (20% vs. 5%), whereas it was similar in the MARCKS-positive vs. MARCKS-negative IBC patients (45% vs. 49%, respectively); similarly, the percentage of TN patients was 3.5-time higher in the MARCKS-positive vs. MARCKS-negative nIBC patients (37% vs. 11%), whereas it was 2-time higher in the MARCKS-positive vs. MARCKS-negative IBC patients (21% vs. 9%, respectively). Here, MARCKS is linked to inflammatory breast carcinoma.